BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18985627)

  • 1. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
    Feldman HH; Pirttila T; Dartigues JF; Everitt B; Van Baelen B; Schwalen S; Kavanagh S
    Int J Geriatr Psychiatry; 2009 May; 24(5):479-88. PubMed ID: 18985627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of mortality risk in patients with dementia treated with galantamine.
    Feldman HH; Pirttila T; Dartigues JF; Everitt B; Van Baelen B; Brashear HR; Berlin JA; Battisti WP; Kavanagh S
    Acta Neurol Scand; 2009 Jan; 119(1):22-31. PubMed ID: 18518863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
    Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R
    J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.
    Mintzer JE; Kershaw P
    Int J Geriatr Psychiatry; 2003 Apr; 18(4):292-7. PubMed ID: 12673604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
    Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
    No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.
    Senanarong V; Poungvarin N; Phanthumchinda K; Thavichachart N; Chankrachang S; Praditsuwan R; Nidhinandana S
    J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S12-8. PubMed ID: 19562980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
    Tangwongchai S; Thavichachart N; Senanarong V; Poungvarin N; Phanthumchinda K; Praditsuwan R; Nidhinandana S; Chankrachang S
    Am J Alzheimers Dis Other Demen; 2008 Dec-2009 Jan; 23(6):593-601. PubMed ID: 18845693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment.
    Vellas B; Lauque S; Gillette-Guyonnet S; Andrieu S; Cortes F; Nourhashémi F; Cantet C; Ousset PJ; Grandjean H;
    J Nutr Health Aging; 2005; 9(2):75-80. PubMed ID: 15791349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
    Wattmo C; Wallin AK; Londos E; Minthon L
    Gerontologist; 2011 Feb; 51(1):17-27. PubMed ID: 20562471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
    Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
    J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey.
    Froelich L; Andreasen N; Tsolaki M; Foucher A; Kavanagh S; Baelen BV; Schwalen S
    Curr Med Res Opin; 2009 Dec; 25(12):3059-68. PubMed ID: 19852697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
    Sano M; Wilcock GK; van Baelen B; Kavanagh S
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.